Laparoscopic Power Morcellators Market Size, Share & Trends Analysis Report By Application (Hysterectomy, Myomectomy), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2021 - 2028

Report Overview

The global laparoscopic power morcellators market size was valued at USD 107.3 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.4% from 2021 to 2028. The increasing prevalence of uterine fibroids among women globally, the rise in preference for minimally invasive gynecological procedures, as well as technological advancements in surgical devices are the major factors expected to drive the market. Power morcellators are less invasive devices that are utilized during procedures such as fibroid removal or hysterectomy, for cutting tissues into smaller pieces.

The market for laparoscopic power morcellators has been moderately impacted by COVID-19 owing to delay or cancellation of numerous elective surgeries, including hysterectomy/myomectomy, as many hospitals closed outpatient facilities in order to limit the spread of the disease and prioritize the treatment of COVID-19 patients. This in turn has limited the usage of surgical devices in hospitals for a short period. However, the European Society for Gynecological Endoscopy and the American Association of Gynecologic Laparoscopists have issued guidelines to continue performing minimally/non-invasive surgery in case of emergency. As the restrictions on easing elective procedures are being resolved in most countries, it is expected that the market for laparoscopic power morcellators will not only experience impetus during the forecast period but will also continue to witness a substantial growth rate after the end of the pandemic.

Prevalence of uterine fibroids in women is on the rise globally, and these can lead to abnormal uterine bleeding, amenorrhea, dysmenorrhea (painful and heavy menstrual periods), and pelvic or abdominal pressure. It is estimated that not all women with uterine fibroids have symptoms and around 50 to 75% of cases remain asymptomatic and often remain undiagnosed. Thus, it is estimated that around 77% of women of childbearing age could have uterine fibroids. According to an NCBI study report, in the U.S., around 30,000 myomectomies are performed annually for leiomyomata (fibroids). The prevalence of uterine fibroids increases as women age and may occur in over 30% of women aged between 40 to 60 years. Furthermore, according to the U.S. National Institutes of Health, in 2017 an estimated 793,846 women were diagnosed with uterine cancer. The rate of new cases of uterine cancer was 27.8 per 100,000 females per year. This supports the growth of uterine fibroid treatment. Thus, the rising prevalence of uterine fibroids is increasing the demand for myomectomy or hysterectomy procedures worldwide, thereby boosting the growth of the market for laparoscopic power morcellators over the forecast period.

Additionally, minimally invasive and non-invasive surgeries are gaining popularity these days owing to the reduced risk associated with such procedures. Smaller cuts minimize postoperative pain and facilitate speedy recovery leading to high adoption of these procedures. Nowadays, surgeons are performing single-port laparoscopic and robotic myomectomies/hysterectomies to remove larger fibroids. These can be removed through minor incisions by breaking them into pieces called morcellation with the help of laparoscopic power morcellators. Thus, the risks of blood loss and infection are lower with minimally invasive procedures when compared to open abdomen surgeries. Such procedures also allow shorter hospital stays and the patient can get back to work and perform normal activities within a short span. Therefore, advantages such as these are cumulatively responsible to fuel the demand for minimally invasive surgeries, thereby driving the market for laparoscopic power morcellators.

The U.S. dominated the regional market for laparoscopic power morcellators with the largest revenue share of 85.0% in 2020 owing to the increasing number of uterine fibroids cases and related surgeries, along with the growing awareness related to treatment among the general population. For instance, uterine fibroids are the indication for hysterectomy and account for 39.0% of all hysterectomies performed annually in the U.S. Moreover, according to the American Journal of Obstetrics and Gynecology, in the U.S., over one-third of hysterectomies are performed for uterine fibroids. Thus, the rising number of hysterectomy surgeries is also expected to positively impact the growth of the market for laparoscopic power morcellators over the forecast period. Furthermore, technological advancements, coupled with launches of new and innovative products, are among the key factors fueling the growth of the market for laparoscopic power morcellators in the country.

Additionally, growing awareness programs by various organizations are increasing the demand for fibroid treatment devices worldwide. In the U.S., July is being recognized as “Fibroid Awareness Month”. This means knowing more about an extremely prevalent gynecological condition that affects as many as 8 out of 10 women by the age of 50. In recent years, there have been efforts to increase awareness related to uterine fibroids. The White Dress Project, HealthyWomen.org, The Fibroids Project, Fibroid and Fertility Coach and author, and Center for Innovative GYN Care are some of the notable programs related to fibroids awareness and treatment.

For instance, the Healthy Women Project’s mission is to engage and educate on new, FDA-approved treatments and procedures. They have strong partnerships with both patients and health professional organizations and promote extended audiences with program and campaign offerings through social media. Thus, all these initiatives taken by the government and non-profit organizations for the treatment of uterine fibroids are expected to boost the growth of the market for laparoscopic power morcellators during the forecast period.

Application Insights

The hysterectomy segment dominated the market for laparoscopic power morcellators and accounted for the largest revenue share of 70.5% in 2020. The segment is also expected to witness the highest CAGR of 7.7% from 2021 to 2028. This procedure is the most preferred and proven permanent solution for uterine fibroids, thus, contributing to the growth of the segment. This procedure can permanently eliminate uterine fibroids. However, pregnancy is impossible after this procedure. For instance, as per the Journal of Obstetrics and Gynecology Canada (JOCG), over 41,000 hysterectomies are performed every year in Canada. Thus, the rising number of hysterectomy surgeries is expected to positively impact segment growth over the forecast period.

However, myomectomy procedure is considered as standard care for eliminating fibroids and preserving the uterus and provides patients the opportunity to remain fertile. This procedure can preserve fertility, unlike a hysterectomy. There are different ways to perform a myomectomy depending on the size and location of the fibroids. Nowadays, some surgeons are performing single-port (one incision) laparoscopic and robotic myomectomies. Larger fibroids can be removed through minor incisions by breaking them into pieces called morcellation to remove the fibroids. Thus, an increase in the number of patient preferences for non-invasive treatment is expected to boost segment growth at a significant rate during the forecast period.

Regional Insights

North America dominated the laparoscopic power morcellators market and accounted for the largest revenue share of 52.8% in 2020. Factors such as increasing gynecological surgical procedures/hospital visits, the presence of well-established healthcare facilities, as well as rising government initiatives are anticipated to increase the demand for laparoscopic power morcellators in the region during the forecast period. Furthermore, the availability of technologically advanced products and the presence of major key players are also contributing towards the growth of the market for laparoscopic power morcellators in the region.

In the Asia Pacific, the market for laparoscopic power morcellators is expected to witness the highest CAGR of 8.6% from 2021 to 2028. The rising patient pool suffering from various disorders such as uterine fibroids, endometritis, abnormal bleeding, and subsequent increase in the number of myomectomy and hysterectomy surgeries is expected to boost the demand for laparoscopic power morcellators in the Asia Pacific in the coming years. Moreover, an increase in the number of hospitalizations, rising awareness regarding women’s health, and improving health spending are few other factors supporting market growth in this region.

Key Companies & Market Share Insights

The key players are stressing on research and development activities to develop technologically advanced products to make morcellators safe. For instance, in May 2018, Intuitive Surgical, a global healthcare company that specializes in minimally invasive and robotic-assisted surgeries, announced the U.S. FDA approval for its “Single Port Platform” - the da Vinci SP Surgical System that utilizes various urologic surgical procedures. This system enables surgeons with robotic-assisted technology intended for deep and narrow access to tissue.

Moreover, major players are adopting various strategies such as new product launches, mergers and acquisitions, and geographic expansion to gain more share in the market for laparoscopic power morcellators. For instance, in October 2019, Ethicon, Inc., and Olympus Corporation have signed an agreement in which Olympus will acquire all new business activities from Ethicon related to the Versapoint Electrosurgery system. Similarly, in May 2020, Minerva Surgical acquired the Intrauterine Health products segment from Boston Scientific Corporation. The products include Symphion Tissue Removal System, Resect Tissue Resection Device, and the Genesys HTA System utilized for the treatment of irregular uterine bleeding and other related disorders. Thus, such developments are expected to significantly influence market growth over the forecast period. Some of the prominent players in the laparoscopic power morcellators market include:

• Medtronic

• Karl Storz GmbH

• Richard Wolf GmbH

• LiNA Medical

• Lumenis (Boston Scientific Corporation)

• Nouvag AG

• Olympus Corporation

• RUDOLF Medical GmbH

Laparoscopic Power Morcellators Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global laparoscopic power morcellators market report on the basis of application and region:

• Application Outlook (Revenue, USD Million, 2016 - 2028)

  • Hysterectomy

  • Myomectomy

  • Others

• Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East & Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE